MONOCLONAL ANTIBODY FOR CANCER TREATMENT (Q3133637)

From EU Knowledge Graph
Revision as of 08:49, 2 December 2021 by DG Regio (talk | contribs) (‎Created claim: summary (P836): VALIDATION D’UN ANTICORPS MONOCLONAL POUR LA DÉTECTION ET LE TRAITEMENT DES CELLULES SOUCHES CANCÉREUSES DANS LES TUMEURS CÉRÉBRALES, translated_summary)
Jump to navigation Jump to search
Project Q3133637 in Spain
Language Label Description Also known as
English
MONOCLONAL ANTIBODY FOR CANCER TREATMENT
Project Q3133637 in Spain

    Statements

    0 references
    0 references
    28,123.69 Euro
    0 references
    56,247.39 Euro
    0 references
    50.0 percent
    0 references
    16 February 2015
    0 references
    14 December 2015
    0 references
    ALTHIA HEALTH S.L.
    0 references
    0 references
    0 references

    40°25'0.12"N, 3°42'12.89"W
    0 references
    28079
    0 references
    VALIDACIÓN DE UN ANTICUERPO MONOCLONAL PARA LA DETECCIÓN Y TRATAMIENTO DE CÉLULAS MADRE DEL CÁNCER EN TUMORES DE CEREBRO (Spanish)
    0 references
    VALIDATION OF A MONOCLONAL ANTIBODY FOR THE DETECTION AND TREATMENT OF CANCER MOTHER CELLS IN BRAIN TUMORS (English)
    0 references
    VALIDATION D’UN ANTICORPS MONOCLONAL POUR LA DÉTECTION ET LE TRAITEMENT DES CELLULES SOUCHES CANCÉREUSES DANS LES TUMEURS CÉRÉBRALES (French)
    2 December 2021
    0 references
    Madrid
    0 references

    Identifiers

    DGEPF/01/21/002-17/18
    0 references